Year None2021202020192018201720162015201420122011201020092008

September 8, 2021

Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

September 7, 2021

Albireo Sells Priority Review Voucher (PRV) for $105 Million

September 2, 2021

Albireo to Present at Upcoming Investor Conferences

August 5, 2021

Albireo Reports Q2 Financial Results and Business Update

August 3, 2021

Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

July 29, 2021

Albireo to Report Second Quarter 2021 Financial Results on August 5

July 20, 2021

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

July 20, 2021

Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

July 19, 2021

Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)

July 8, 2021

Albireo to Present at the William Blair Biotech Focus Conference 2021

• Email Alerts
• RSS
• Print